KZR vs. NLTX, ZNTL, PRQR, CRDF, CGEN, ACRS, SLN, CYBN, SCPH, and GNFT
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Neoleukin Therapeutics (NLTX), Zentalis Pharmaceuticals (ZNTL), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Compugen (CGEN), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), Cybin (CYBN), scPharmaceuticals (SCPH), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry.
Kezar Life Sciences vs.
Neoleukin Therapeutics (NASDAQ:NLTX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
Neoleukin Therapeutics' return on equity of -37.22% beat Kezar Life Sciences' return on equity.
In the previous week, Neoleukin Therapeutics and Neoleukin Therapeutics both had 1 articles in the media. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.01 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.
Kezar Life Sciences received 86 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 56.90% of users gave Kezar Life Sciences an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.
Kezar Life Sciences has a consensus price target of $39.50, indicating a potential upside of 538.13%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kezar Life Sciences is more favorable than Neoleukin Therapeutics.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Neoleukin Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Kezar Life Sciences beats Neoleukin Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Kezar Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KZR) was last updated on 1/21/2025 by MarketBeat.com Staff